Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a ...

Madrigal Pharmaceuticals Inc (MDGL) reports robust financial performance with significant milestones in Rezdiffra's launch ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) reached a new 52-week high on Thursday after the company announced better than expected quarterly earnings. The stock traded as high as ...

BofA raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $239 from $154 and keeps an Underperform rating on ...

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price ...

Benzinga's options scanner spotted 9 options trades for Madrigal Pharmaceuticals. This is not a typical pattern. The sentiment among these major traders is split, with 44% bullish and 44% bearish.

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...

Madrigal Pharmaceuticals (MDGL) reported Q4 results and provided a 2-year update from the open-label metabolic dysfunction-associated ...

Investing.com -- Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: NASDAQ: MDGL) rose 17% following the announcement of their fourth-quarter and full-year 2024 financial results, which included a ...

Madrigal posted a Q4 loss of $2.71 per share ... and are well positioned for strong performance again in 2025 and beyond." Price Action: MDGL stock is up 20.30% at $372.26 at the last check ...